Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 98

1.

Long term results of treatment of breast cancer without axillary surgery - Predicting a SOUND approach?

O'Connell RL, Rusby JE, Stamp GF, Conway A, Roche N, Barry P, Khabra K, Bonomi R, Rapisarda IF, Della Rovere GQ.

Eur J Surg Oncol. 2016 Jul;42(7):942-8. doi: 10.1016/j.ejso.2016.03.027. Epub 2016 Apr 13.

PMID:
27117580
2.

Long-term prognoses and outcomes of axillary lymph node recurrence in 2,578 sentinel lymph node-negative patients for whom axillary lymph node dissection was omitted: results from one Japanese hospital.

Ogiya A, Kimura K, Nakashima E, Sakai T, Miyagi Y, Iijima K, Morizono H, Makita M, Horii R, Akiyama F, Iwase T.

Breast Cancer. 2016 Mar;23(2):318-22. doi: 10.1007/s12282-014-0576-5. Epub 2014 Nov 7.

PMID:
25376341
3.

Completion axillary lymph node dissection not required for regional control in patients with breast cancer who have micrometastases in a sentinel node.

Yegiyants S, Romero LM, Haigh PI, DiFronzo LA.

Arch Surg. 2010 Jun;145(6):564-9. doi: 10.1001/archsurg.2010.84.

PMID:
20566977
4.

Predicting axillary sentinel node status in patients with primary breast cancer.

Kolarik D, Pecha V, Skovajsova M, Zahumensky J, Trnkova M, Petruzelka L, Halaska M, Sottner O, Otcenasek M, Kolarova H.

Neoplasma. 2013;60(3):334-42. doi: 10.4149/neo_2013_045.

PMID:
23374005
5.

Axillary dissection versus no axillary dissection in patients with sentinel-node micrometastases (IBCSG 23-01): a phase 3 randomised controlled trial.

Galimberti V, Cole BF, Zurrida S, Viale G, Luini A, Veronesi P, Baratella P, Chifu C, Sargenti M, Intra M, Gentilini O, Mastropasqua MG, Mazzarol G, Massarut S, Garbay JR, Zgajnar J, Galatius H, Recalcati A, Littlejohn D, Bamert M, Colleoni M, Price KN, Regan MM, Goldhirsch A, Coates AS, Gelber RD, Veronesi U; International Breast Cancer Study Group Trial 23-01 investigators.

Lancet Oncol. 2013 Apr;14(4):297-305. doi: 10.1016/S1470-2045(13)70035-4. Epub 2013 Mar 11. Erratum in: Lancet Oncol. 2013 Jun;14(7):e254.

6.

[Management of the axilla in breast cancer: evidences and unresolved issues].

Fodor J, Polgár C, Péley G, Németh G.

Orv Hetil. 2001 Sep 9;142(36):1941-50. Review. Hungarian.

PMID:
11680099
7.

Staging and management of axillary lymph nodes in patients with local recurrence in the breast or chest wall after a previous negative sentinel node procedure.

Derkx F, Maaskant-Braat AJ, van der Sangen MJ, Nieuwenhuijzen GA, van de Poll-Franse LV, Roumen RM, Voogd AC.

Eur J Surg Oncol. 2010 Jul;36(7):646-51. doi: 10.1016/j.ejso.2010.05.009. Epub 2010 May 26.

PMID:
20537838
8.

Can we avoid axillary dissection in the micrometastatic sentinel node in breast cancer?

Galimberti V, Botteri E, Chifu C, Gentilini O, Luini A, Intra M, Baratella P, Sargenti M, Zurrida S, Veronesi P, Rotmensz N, Viale G, Sonzogni A, Colleoni M, Veronesi U.

Breast Cancer Res Treat. 2012 Feb;131(3):819-25. doi: 10.1007/s10549-011-1486-2. Epub 2011 Apr 6.

PMID:
21468637
9.

Axillary recurrences after negative sentinel lymph node biopsy under local anaesthesia for breast cancer: a follow-up study after 5 years.

Groetelaers RP, van Berlo CL, Nijhuis PH, Schapers RF, Gerritsen HA.

Eur J Surg Oncol. 2009 Feb;35(2):159-63. doi: 10.1016/j.ejso.2008.07.017. Epub 2008 Sep 11.

PMID:
18789841
10.

Second Axillary Sentinel Lymph Node Biopsy for Breast Tumor Recurrence: Experience of the European Institute of Oncology.

Intra M, Viale G, Vila J, Grana CM, Toesca A, Gentilini O, Galimberti V, Veronesi P, Luini A, Rotmensz N, Bagnardi V, Mattar D, Colleoni M.

Ann Surg Oncol. 2015 Jul;22(7):2372-7. doi: 10.1245/s10434-014-4282-5. Epub 2014 Dec 17.

PMID:
25515197
11.

Erratum to: Axillary recurrence rate following negative sentinel node biopsy for invasive breast cancer: long-term follow-up.

Kiluk JV, Ly QP, Santillan AA, Meade T, Ramos D, Reintgen DS, Dessureault S, Davis M, Shamehdi C, Cox CE.

Ann Surg Oncol. 2010 Feb;17(2):552-7. doi: 10.1245/s10434-009-0800-2.

PMID:
19957043
12.

Treatment of the axilla in early breast cancer: past, present and future.

Chua B, Ung O, Boyages J.

ANZ J Surg. 2001 Dec;71(12):729-36.

PMID:
11906388
13.

Axillary recurrence in women with a negative sentinel lymph node and no axillary dissection in breast cancer.

Palesty JA, Foster JM, Hurd TC, Watroba N, Rezaishiraz H, Edge SB.

J Surg Oncol. 2006 Feb 1;93(2):129-32.

PMID:
16425295
14.

Omission of axillary lymph node dissection for clinically node negative early-stage breast cancer patients.

Kobayashi R, Shiraishi K, Iwase S, Ohtomo K, Nakagawa K.

Breast Cancer. 2015 Nov;22(6):657-63. doi: 10.1007/s12282-014-0532-4. Epub 2014 Apr 23.

PMID:
24756246
15.

Patients with breast cancer and negative sentinel lymph node biopsy without additional axillary lymph node dissection: a follow-up study of up to 5 years.

Domènech A, Benitez A, Bajén MT, Pla MJ, Gil M, Martín-Comín J.

Oncology. 2007;72(1-2):27-32. Epub 2007 Nov 12.

PMID:
17998787
16.

Disease recurrence in sentinel node-positive breast cancer patients forgoing axillary lymph node dissection.

Cyr A, Gao F, Gillanders WE, Aft RL, Eberlein TJ, Margenthaler JA.

Ann Surg Oncol. 2012 Oct;19(10):3185-91. doi: 10.1245/s10434-012-2547-4. Epub 2012 Aug 14.

17.

Breast cancer patients with extra-axillary sentinel nodes only may be spared axillary lymph node dissection.

van der Ploeg IM, Tanis PJ, Valdés Olmos RA, Kroon BB, Rutgers EJ, Nieweg OE.

Ann Surg Oncol. 2008 Nov;15(11):3239-43. doi: 10.1245/s10434-008-0120-y. Epub 2008 Sep 5.

PMID:
18773244
18.

Conservative axillary surgery in breast cancer patients undergoing mastectomy: long-term results.

Cowher MS, Grobmyer SR, Lyons J, O'Rourke C, Baynes D, Crowe JP.

J Am Coll Surg. 2014 Apr;218(4):819-24. doi: 10.1016/j.jamcollsurg.2013.12.041. Epub 2014 Jan 17.

PMID:
24655877
19.

Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomised phase 3 trial.

Krag DN, Anderson SJ, Julian TB, Brown AM, Harlow SP, Costantino JP, Ashikaga T, Weaver DL, Mamounas EP, Jalovec LM, Frazier TG, Noyes RD, Robidoux A, Scarth HM, Wolmark N.

Lancet Oncol. 2010 Oct;11(10):927-33. doi: 10.1016/S1470-2045(10)70207-2.

Supplemental Content

Support Center